Compare BCV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCV | CHRS |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.7M | 159.1M |
| IPO Year | 1995 | 2014 |
| Metric | BCV | CHRS |
|---|---|---|
| Price | $21.03 | $0.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 10.9K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.19 |
| Revenue Next Year | N/A | $65.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.06 | $0.75 |
| 52 Week High | $27.33 | $2.62 |
| Indicator | BCV | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 34.91 | 35.98 |
| Support Level | N/A | N/A |
| Resistance Level | $22.72 | $1.53 |
| Average True Range (ATR) | 0.48 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 6.70 | 7.57 |
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.